Ocular Therapeutix™ Announces Antony Mattessich Assumes Role as Chief Executive Officer

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced that in line with the Company’s strategic plan and growth objectives announced in June 2017, Antony Mattessich has assumed the role of Chief Executive Officer, effective immediately. Former CEO Dr. Amar Sawhney has transitioned to Executive Chairman of